Correction to: Cardiovasc Diabetol (2017) 16:8 DOI 10.1186/s12933-016-0491-5
Following publication of the original article [1], the authors identified a number of errors. In Result (P.3), Table 1 (P.4), Table 5 (P.9) and Supplementary Table 1, the correct unit for adiponectin was μg/mL. In Table 1 (P.4), the correct value for the post treatment body weight in dapagliflozin was 76.2±14.8. In Table 6 (P.10), the correct value for the pre treatment sd LDL/LDL-C in decreased LDL-C group was 0.38±0.10.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Footnotes
The online version of the original article can be found under doi:10.1186/s12933-016-0491-5.
Contributor Information
Toshiyuki Hayashi, Email: t-hayashi@med.showa-u.ac.jp.
Tomoyasu Fukui, Email: tomoyasufk@yahoo.co.jp.
Noriko Nakanishi, Email: nori-nnori@hotmail.co.jp.
Saki Yamamoto, Email: sakichakko@gmail.com.
Masako Tomoyasu, Email: goodnews0911@yahoo.co.jp.
Anna Osamura, Email: annatoku@gmail.com.
Makoto Ohara, Email: s6018@nms.ac.jp.
Takeshi Yamamoto, Email: tak3105@aol.com.
Yasuki Ito, Email: y_ito@denka-seiken.co.jp.
Tsutomu Hirano, Email: hirano@med.showa-u.ac.jp.
Reference
- 1.Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16:8. doi: 10.1186/s12933-016-0491-5. [DOI] [PMC free article] [PubMed] [Google Scholar]